NeoGenomics to present at NextGen Omics Spatial and Data U.S. 2026 on immunotherapy resistance mapping

NeoGenomics to present at NextGen Omics Spatial and Data U.S. 2026 on immunotherapy resistance mapping
NeoGenomics reveals spatial biology research

NeoGenomics will participate in the NextGen Omics Spatial and Data U.S. 2026 event with a special presentation focused on overcoming immunotherapy resistance.

The company plans to provide new insights into spatial biology and its role in unraveling the complexities of the tumor microenvironment, a key challenge for advancing cancer therapies. Attendees will have the opportunity to explore innovative research aimed at improving responses to immunotherapy.

The company’s focus on spatial biology builds upon its recent advancements, including the introduction of PanTracer Pro for advanced-stage solid tumors. These ongoing efforts to simplify molecular testing workflows, further detailed in the unveiling of PanTracer Pro to enhance patient care, underscore NeoGenomics’ commitment to innovation in oncology diagnostics as it addresses the pressing challenges of immunotherapy resistance.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.